FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.
Myriad Genetics Submits Supplementary PMA for BRACAnalysis CDx
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
PARP Inhibitor Resistance Gene Identified Using CRISPR Screen
Researchers used CRISPR-Cas9 screening assays in mouse and human cells to track down point mutations in the PARP1 gene that boost resistance to PARP inhibitor drugs.
Pfizer PARP Inhibitor Delays Progression Over Chemotherapy in BRCA-Mutated Advanced Breast Cancer
In a Phase III trial, talazoparib-treated patients had a three-month median progression-free survival advantage over patients treated with chemotherapy chosen by their doctors.